WALTHAM, Mass., May 14, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq: TSRO ), an oncology-focused biopharmaceutical company, today announced the presentation of six abstracts at the 2014 American Society of Clinical Oncology (ASCO) annual meeting, May 30 to June 3, 2014, in Chicago. The presentations will include detailed results from the three Phase 3 trials of rolapitant, an investigational neurokinin-1, or NK-1, receptor antagonist in development for the prevention of chemotherapy-induced nausea and vomiting (CINV), and data from a Phase 1 combination study of niraparib, an orally active inhibitor of poly (ADP-ribose) polymerase, or PARP.
ASCO Presentation Details
| Rolapitant: |
| Phase 3 trial results for rolapitant, a novel NK-1 receptor antagonist, in the prevention of chemotherapy-induced nausea and vomiting (CINV) in subjects receiving moderately emetogenic chemotherapy (MEC) |
| June 1, 2014 8:00 AM - 11:45 AM |
| Abstract #9633, Poster Board: #283, Patient and Survivor Care Track |
| Safety of rolapitant, a novel NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic chemotherapy (MEC or HEC) |
| June 1, 2014 8:00 AM - 11:45 AM |
| Abstract #9636, Poster Board: #286, Patient and Survivor Care Track |
| Phase 3 trial results for rolapitant, a novel NK-1 receptor antagonist, in the prevention of chemotherapy-induced nausea and vomiting (CINV) in subjects receiving highly emetogenic chemotherapy (HEC) |
| June 1, 2014 8:00 AM - 11:45 AM |
| Abstract #9638, Poster Board: #288, Patient and Survivor Care Track |
| Phase 1 positron emission tomography (PET) study of the receptor occupancy of rolapitant, a novel NK-1 receptor antagonist |
| Abstract #e20690, Publication only |
| Niraparib: |
| A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer (ENGOT-OV16/NOVA trial) |
| May 31, 2014 8:00 AM - 11:45 AM |
| Abstract #TPS5625, Poster Board: #400A, Gynecologic Cancer Track |
| A phase I study of niraparib in combination with temozolomide (TMZ) in patients with advanced cancer |
| May 31, 2014 1:15 PM - 5:00 PM |
| Abstract #2092, Poster Board: #57, Central Nervous System Tumors Track |
| A phase 3 randomized trial of niraparib versus physician's choice in previously treated, HER2-negative, germline-BRCA mutated breast cancer patients: Intergroup study EORTC-1307-BCG and BIG5-13 |
| June 2, 2014 8:00 AM - 11:45 AM |
| Abstract #TPS659, Poster Board: #119B, Breast Cancer Track |
| Food Effect Sub Study of a Phase 3 Randomized Double-blind Trial of Maintenance with Niraparib (MK4827), a Poly(ADP)ribose Polymerase (PARP) Inhibitor versus Placebo in Patients with Platinum Sensitive Ovarian Cancer |
| Abstract #e16531, Publication only |
| TSR-011: |
| Phase 1/2 study of TSR-011, a potent inhibitor of ALK and TRK, including crizotinib-resistant mutations |
| Abstract #e19005, Publication only |
Investor Briefing
TESARO will host an investor briefing in Chicago on Sunday, June 1 at 6:15 PM local time in conjunction with the ASCO annual meeting. At this briefing, TESARO management will review rolapitant clinical data, discuss the niraparib development strategy and provide an update on its TSR-011 and immuno-oncology programs. In addition to members of the senior management team of TESARO, Jeffrey Patton, M.D. of Tennessee Oncology, a practicing oncologist with extensive experience in the treatment of patients with a variety of cancers, and Drew Pardoll, M.D., Ph.D. of Johns Hopkins University, an expert in immuno-oncology approaches such as those targeting PD-1, TIM-3, LAG‑3 and other immune regulators, will take part in discussions with investors. This event will be webcast live and archived for 30 days, and may be accessed from the TESARO Investor Events and Presentations webpage at www.tesarobio.com .
About TESARO
TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by acquiring, developing and commercializing safer and more effective therapeutics. For more information, visit www.tesarobio.com .
To the extent that statements contained in this press release are not descriptions of historical facts regarding TESARO, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward looking statements contained in this press release include, among others, statements regarding our expectations regarding our development programs for our product candidates. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the initiation of future clinical trials, availability of data from ongoing clinical trials, expectations for regulatory approvals, and other matters that could affect the availability or commercial potential of our drug candidates. TESARO undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see TESARO's Annual Report on Form 10-K for the year ended December 31, 2013 and other filings TESARO makes with the Securities and Exchange Commission.
Investor/Media Contact: Jennifer Davis Sr. Director, Corporate Development & Investor Relations +1.781.325.1116 or
